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Introduction: Vascular surgeries are related to high cardiac morbidity and mortality, and the maintenance of aspirin in the
perioperative period has a protective effect. The purpose of this study was to evaluate the association between preoperative
platelet aggregability and perioperative cardiovascular (CV) events.
Methods: A preoperative platelet aggregation test was performed on an impedance aggregometer in response to collagen
and to arachidonic acid (AA) for 191 vascular surgery patients under chronic use of aspirin. We analyzed the following CV
events: acute myocardial infarction, unstable angina, isolated troponin elevation, acute ischemic stroke, reoperation, and
cardiac death. Hemorrhagic events were also evaluated and classiﬁed according to the Thrombolysis In Myocardial
Infarction criteria.
Results: The incidence of CV events was 22% (n[ 42). Higher platelet response to AA was associated with CV events, so
that patients in the fourth quartile (higher than 11U) had almost twice the incidence of CV events when compared with
the three lower quartiles: 35% vs 19%; P[ .025. The independent predictors of CV events were hemodynamic instability
during anesthesia (odds ratio [OR], 4.12; 95% conﬁdence interval [CI], 1.87-9.06; P < .001), dyslipidemia (OR, 3.9; 95%
CI, 1.32-11.51; P[ .014), preoperative anemia (OR, 2.64; 95% CI, 1.19-5.85; P[ .017), and AA platelet aggregability
in the upper quartile (OR, 2.48; 95% CI, 1.07-5.76; P [ .034). Platelet aggregability was not associated with hemor-
rhagic events, even when we compared the lowest quartile of AA platelet aggregability (0-1.00 U) with the three upper
quartiles (>1.00 U; OR, 0.77; 95% CI, 0.43-1.37; P [ .377).
Conclusions: The degree of aspirin effect on platelet aggregability maybe important in the management of perioperative
CV morbidity, without increment in the bleeding toll. (J Vasc Surg 2013;58:1593-9.)Vascular surgeries are related to high morbidity mainly
due to acute cardiac events.1 Recent data unraveled the great
debate regarding the underlying mechanism of perioperative
myocardial ischemia, and the current concept is that, besides
myocardial oxygen supply and demand mismatch, the clas-
sical atherothrombosis is a determinant factor.2
The perioperative use of beta-blockers attenuates the
oxygen mismatch,3-5 while statins6-8 and acetylsalicylic acid9
are targeted for atherothrombosis prevention.
The American Heart Association and American College
of Cardiology Guidelines (AHA/ACC),1 the European
Society of Cardiology (ESC) guidelines,10 and the Brazil-
ian Society of Cardiology guidelines for perioperative eval-
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://dx.doi.org/10.1016/j.jvs.2013.06.061in the perioperative period of vascular surgeries as the beneﬁt
of platelet anti-aggregation outweighs the bleeding risk.12,13
Burger et al have found in theirmeta-analysis that the discon-
tinuation of aspirin can trigger the occurrence of cardiac,
cerebrovascular, and peripheral arterial events, while the
continued use of aspirin in the perioperative period of
noncardiac surgeries does not increase the mortality and
morbidity, despite a 50% increase in the bleeding risk.12
Oscarsson et al found a reduction in cardiovascular (CV)
events 30 days after noncardiac surgery in patients random-
ized to maintain aspirin perioperatively without a signiﬁcant
increase in the bleeding tendency.9 The purpose of the
present study is to evaluate if the level of platelet aggregation
inﬂuences the perioperative CV adverse event rate, consid-
ering that there is a great variability in individual responsive-
ness for aspirin therapy.14-16
The test to evaluate the effect of aspirin is based on the
platelet aggregation response to arachidonic acid (AA), which
is the substrate of cyclooxygenase 1 that is inhibitedby aspirin.
It canbeperformedwith thepoint-of-careVerify-Now(Accu-
metrics Inc, San Diego, Calif) system or with optical aggreg-
ometry or impedance aggregometry in the whole blood.
METHODS
This protocol was approved by the local Ethics
Committee, and patients were enrolled after giving their
written informed consent.
Patients were considered eligible for the study if they
were admitted to the hospital for an elective vascular surgery1593
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were under chronic and continuous use of aspirin, regard-
less of the aspirin dosage. The exclusion criteria were:
use of other antiplatelet agent (clopidogrel, prasugrel, or
dipyridamole); platelet transfusion; treatment with warfarin;
use of nonsteroidal anti-inﬂammatory drug in the past
week; acute coronary syndrome; myocardial revasculari-
zation or stroke in the previous 3 months; current malig-
nancy; current infection; and platelet count below
100,000/mL.
Detailed medical history and preoperative medication
use were obtained from the patients and relatives. Resting
12-derivation electrocardiogram, chest radiography, creati-
nine, electrolytes, lipid proﬁle, blood glucose levels, and
complete blood count were obtained for all patients.
Cardiac risk estimate and myocardial perfusion stress
testing indications were based on the current guidelines
for perioperative evaluation from the AHA/ACC1 and
from the Brazilian Society of Cardiology.11 Intraoperative
data regarding duration of anesthesia and hemodynamic
instability, deﬁned as hypotension or bradycardia requiring
vasopressors, necessity of blood transfusion, lowest hemo-
globin level, and highest creatinine level were all computed
for analysis, and an equal or above 50% increase in the base-
line creatinine level was deﬁned as acute kidney injury
(AKI).17
Platelet aggregation tests
To test platelet aggregation before surgery, we per-
formed whole blood impedance aggregometry (Chrono-
log Corp, Havertown, Pa) up to 180 minutes after blood
collection. The blood samples were obtained by venipunc-
ture, early in the morning after an 8-hour fast period, and
were carefully handled in sodium citrate tubes (3.2%
concentration). Maximum extent of aggregation, measured
in ohms, assesses the amount of platelet aggregates after
exposure to each of the following agonists: collagen 1 mg/
mL; collagen 2 mg/mL; collagen 5 mg/mL; and AA
0.5 mM. In short, the accumulation of platelet aggregate
adds electrical resistance to a circuit inserted into the test
sample. Initially, a positive voltage is applied to the circuit
to stimulate initial platelet aggregation. After a stable imped-
ance value is obtained, one of the agonists is added to the
system, stimulating further platelet aggregation that adds
electrical resistance to the circuit. This change in impedance
is measured and quantiﬁed in ohms, and higher levels mean
greater platelet aggregation. The AA agonist is the most
important agent in the present study because it is the
substrate to cyclooxygenase and is converted to throm-
boxane A2. Aspirin inhibits this pathway, determining
a reduction in aggregation in response to AA. This method
is already validated and is a reliable toll for the measurement
of aspirin response.18 The collagen does not speciﬁcally eval-
uate aspirin action, although it is extremely important as
a physiological stimulus to platelet aggregation. The
different collagen concentrations allows the evaluation of
platelet function besides the aspirin effect; it is expected
that patients under aspirin therapy could show poor plateletaggregation to lower concentrations, but when high
collagen concentration is added, their platelet aggregation
should not be inhibited.
CV events
Patients were submitted to CV monitoring for early
event detection by daily cardiologist evaluation until
hospital discharge and electrocardiogram and troponin-T
dosage once a day during the ﬁrst 72 postoperative hours,
repeated as needed.
We deﬁned the following CV events:
Acute myocardial infarction. Detection of a typical
rise and fall of biochemical markers of myocardial necrosis
(cardiac troponin T) with at least one value above the
99th percentile of the upper reference limit together
with ischemic symptoms or development of pathological
Q waves on the electrocardiogram (ECG) or ECG
changes indicative of ischemia (ST segment elevation or
depression) or new regional contractile abnormality in
the echocardiography.
Unstable angina. Ischemic symptoms lasting for at
least 20 minutes with or without ECG changes, without
cardiac troponin elevation.
Isolated cardiac troponin elevation. Troponin level
above the 99th percentile of the upper reference limit
without ischemic symptoms or ECG changes.
Acute ischemic cerebrovascular event. Signs of ische-
mic stroke conﬁrmed with imaging studies (computed tomog-
raphy or magnetic resonance).
Reoperation. New vascular procedure due to throm-
botic complication of the index operation.
Bleeding events
The postoperative bleeding was classiﬁed according to an
adapted Thrombolysis In Myocardial Infarction (TIMI)
criterion, as minor or major bleeding.19,20
Major bleeding. Decrease in hemoglobin >5 g/dL
(or 15% in hematocrit).
Minor bleeding. Decrease in hemoglobin: 3.1 to 5 g/dL
(or 10% in hematocrit).
Importantly, red blood cell transfusion was computed
into the TIMI criteria and each unit of red blood cell
accounted for 1 g/dL.
Sample size and statistics
Sample size was calculated based on the incidence of
CV events after vascular surgery observed in two previous
studies of our group with similar populations: 14.6%21
and 15.5%.6,21 Therefore, we calculated a sample size of
200 patients, for detection of 30 CV events. The study
was designed to have 80% power to detect a difference in
platelet aggregability of 30% or more between patients
with and without a CV event, assuming a conﬁdence
interval (CI) of 95%, two-sided.
Categorical data are presented as frequencies, and
continuous variables are presented as mean and respective
standard deviations. Continuous variables that passed in
the normality test were compared using an unpaired
Table I. Baseline characteristics of the study population
Characteristic
Clinical parameters
Age, years 67.10 6 9.73
Male gender 137 (71.7)
Hypertension 163 (85.3)
Dyslipidemia 142 (74.3)
Diabetes mellitus 54 (28.3)
Smoking status
Current 42 (22.0)
Previous 113 (59.2)
Non-smoker 36 (18.8)
Previous myocardial infarction 44 (23.0)
Angina pectoris 19 (9.9)
Heart failure 43 (22.5)
Preoperative anemia 56 (29.3)
Cardiac risk (American College of
Physicians)
Low 77 (40.3)
Intermediate 101 (52.9)
High 13 (6.8)
Medication
Beta-blocker 133 (69.6)
Statin 188 (98.4)
ACE inhibitor 116 (60.7)
Aspirin dosage
100 mg 170 (89)
200 mg 20 (10.5)
300 mg 1 (0.5)
Laboratory parameters
Platelet count,  103/mL 234 6 82.33
Hemoglobin, g/dL 13.30 6 1.58
White blood cell, /mL 7918 6 2033
Creatinine, mg/dL 1.33 6 0.88
LDL-cholesterol, mg/dL 99.89 6 41.47
HDL-cholesterol, mg/dL 42.05 6 13.22
Triglycerides, mg/dL 146.74 6 89.25
Vascular surgical parameters
Endovascular procedure 95 (49.7)
Conventional procedure 96 (50.3)
Vascular disease
Peripheral arterial obstructive disease 57 (29.8)
Carotid disease 44 (23.0)
Abdominal aortic aneurysm 61 (31.9)
Descending thoracic aortic aneurysm/
dissection
9 (4.7)
Other 20 (10.5)
ACE, Angiotensin-converting enzyme; HDL, high density lipoprotein;
LDL, low density lipoprotein.
Continuous data are presented as mean 6 standard deviation and categoric
data as number (%).
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test. Variables that failed to pass in the normality test were
compared with the nonparametric equivalent tests.
Separate logistic regression stepwise models identiﬁed
the independent predictors of CV and hemorrhagic events.
All univariate variables with a P value <.2 were selected for
the multivariate analysis, and the CV events analysis was
adjusted for the cardiac risk level, predicted according to
the American College of Physicians Guidelines.22 The
adequacies of the models were tested with the Hosmer-
Lemershow goodness-of-ﬁt test. All statistical analysis was
performed using the SPSS 17.0 software (IBM, Armonk,
NY) and a two-tailed 95% CI was considered signiﬁcant.
RESULTS
In total, 206 patients were included in the study
between June 2010 and January 2012, and 15 were
excluded from the analysis because of surgery cancellation.
Baseline and vascular procedure characteristics of the
patients are displayed in Table I.
From the 191 patients submitted to the elective
vascular surgery, 42 (22%) had a CV event during hospital-
ization: 7 acute myocardial infarctions, 2 unstable anginas,
9 isolated troponin elevations, nine acute cerebrovascular
ischemic events, 14 vascular reoperations, and 1 CV death.
The incidence of hemorrhagic events was high: 50.97%,
with 45 minor and 60 major events.
Regarding antiplatelet therapy, aspirin was maintained
for all patients. Patients submitted to endovascular treat-
ment of carotid artery or lower limb arteries received
aspirin plus clopidogrel, started in the ﬁrst hours after
surgery. They received a loading dose of 300 mg and
continued to receive 75 mg per day.
In the univariate analysis, we found that hemodynamic
instability during anesthesia (50% in patients with CV
events vs 24.16% in patients without CV events; P ¼
.001), AKI (33.33% vs 16.78%; P ¼ .019), postoperative
signiﬁcant anemia, deﬁned as the lowest hemoglobin post-
operative level below 9 g/dL, (47.62% vs 30.20%; P ¼
.035), baseline anemia (42.86% vs 25.5%; P ¼ .029), and
dyslipidemia (88.1% vs 70.47%; P ¼ .021) were all signiﬁ-
cantly associated with CV events. The operative time was
nonsigniﬁcantly associated to CV events: 238 minutes for
patients with CV events vs 204 minutes for patients
without CV events (P ¼ .292). Other variables that were
not signiﬁcantly associated with CV events in the univariate
analysis, but that qualiﬁed for the multivariate model entry,
were angina (P ¼ .10), heart failure symptoms (P ¼ .138),
red blood cell transfusion (P ¼ .138), and hemorrhagic
event (P ¼ .114). Platelet aggregation tests results in
patients with and without CV events are displayed in
Table II. We found signiﬁcant association between higher
platelet response to AA and CV events. There is no deﬁn-
itive cut-off for the platelet aggregability tests to deﬁne
aspirin resistance. Some authors consider that any value
above 0 U indicates aspirin resistance,23 others consider
the 3U cut-off,24 but there is no proof until now that thesevalues are the best in screening populations with prognostic
implications. We decided to analyze our data according to
the distribution of the results in our population and strati-
ﬁed the values in quartiles. Post-hoc analysis of these data
was performed categorizing this variable according to quar-
tile distribution: 0-1.00 U; 1.01-4.00 U; 4.01-11.00 U; and
higher than 11.00 U, corresponding to the ﬁrst to fourth
quartile, respectively. The cut-off of 11 U, chosen for anal-
ysis, corresponded to the 75th percentile. Patients in the
fourth quartile had almost twice the incidence of CV events
when compared with the three lower quartiles: 35% vs
18.54%; P ¼ .025.
Table II. Platelet aggregation parameters in patients with and without cardiovascular (CV) events
Test Total CV events þ CV events  P
Impedance aggregometry
Collagen 1 mL/mL (U) 5.48 6 4.28 5.79 6 4.21 5.39 6 4.31 .606
Collagen 2 mL/mL (U) 10.48 6 5.27 11.31 6 5.60 10.25 6 5.17 .250
Collagen 5 mL/mL (U) 16.96 6 5.69 17.95 6 5.41 16.68 6 5.75 .203
AA 0.5 mM/mL (U) 5.83 6 5.90 7.40 6 6.39 5.39 6 5.70 .050
AA, Arachidonic acid.
Data are presented as mean 6 standard deviation.
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aspirin on platelet aggregation level. When we compared
the quartiles of platelet aggregation in response to AA in
patients receiving 100 mg vs higher dosages, we did not
ﬁnd signiﬁcant difference: 38.8% vs 47.6% were in the ﬁrst
quartile, 15.3% vs 9.5% in the second quartile, 24.1% vs
28.6% in the third quartile, and 21.8% of the patients
receiving aspirin 100 mg vs 14.3% of the patients receiving
higher dosages were in the fourth quartile (P ¼ .697),
respectively.
The independent predictors of CV events identiﬁed in
the logistic regression model, adjusted for the predicted
risk according to the American College of Physicians algo-
rithm,22 were AA platelet aggregability in the upper quar-
tile, dyslipidemia, preoperative anemia, and hemodynamic
instability during anesthesia (Table III).
The incidence of hemorrhagic events was 50.97%, with
45 minor and 60 major events, and the variables signiﬁ-
cantly correlated to this complication identiﬁed in the
univariate analysis were smoking, heart failure, normal
preoperative hemoglobin level, conventional open vascular
surgery, absence of clopidogrel prescription in the postop-
erative period, and hemodynamic instability. Diabetes and
male gender qualiﬁed for the multivariate model although
were not signiﬁcantly associated to hemorrhagic events
(P ¼ .076 and P ¼ .148, respectively). The platelet aggreg-
ability in response to collagen and AA was not associated
to hemorrhagic events (Table IV). Not even the lowest
AA platelet aggregability quartile was associated to hemor-
rhagic events, when compared with the three other quar-
tiles: 58.41% vs 51.32%; P ¼ .336.
The independent predictors of the 105 hemorrhagic
events were current smoking status (odds ratio [OR],
5.05; 95% CI, 1.74-14.67; P ¼ .003), hemodynamic
instability (OR, 3.41; 95% CI, 1.53-7.59; P ¼ .003),
conventional open vascular surgery (OR, 1.56; 95%
CI, 1.14-1.77; P ¼ .016), acute kidney injury (OR,
3.28; 95% CI, 1.23-8.77; P ¼ .018), and preoperative
anemia (OR, 0.43; 95% CI, 0.20-0.89; P ¼ .024). We
have also analyzed exclusively the need for red blood
cell transfusion, and 20.4% of our patients received at
least one unit of red blood cells in the postoperative
period, ranging from 2.3% of the patients submitted to
carotid surgery and 15.8% of the patients submitted to
peripheral revascularization to 34.3% of the patients
submitted to aortic aneurysm repair.DISCUSSION
For the ﬁrst time, the present study shows that higher
level of platelet aggregation despite aspirin therapy before
vascular surgery is associated with CV complications. It is
well known that platelet activation and adherence to
damaged endothelium starts thrombus formation that is
very important for hemostasis in the surgical wound but
is also responsible for acute cardiac events. Even in the
surgical wound, sometimes the intensity of the process
can be inappropriate and cause graft or stent thrombosis.
The perfect balance between antithrombotic effect and
no prejudice in hemostasis is very difﬁcult to achieve, and
in our study, we found that greater response to aspirin
was protective against CV complications and, on the other
hand, was not related to increased risk of hemorrhagic
events.
Although higher platelet aggregation level is considered
by many authors a marker of cardiac risk in the context of
chronic coronary disease, mainly after percutaneous revascu-
larization,25-27 there are few reports of platelet aggregation
and perioperative cardiac risk. Burdess et al28 found higher
platelet activation in the perioperative period of vascular
surgery in patients with critical limb ischemia when
compared with patients submitted to surgery because of
intermittent claudication, but differently from our study,
they did not report the incidence of cardiac events and their
correlationwith platelet function. Other authors had already
shown that platelet status correlates positively with the
severity of the peripheral vascular disease even in a clinical
context.29,30
Rajagopalan et al31 have previously observed, in 136
patients undergoing vascular surgery, that the platelet
response to 75-mg aspirin therapy was variable, and at base-
line, 16% of the patients presented aspirin reaction units
above 550, which is considered by some authors a nonre-
sponsiveness parameter according to the VerifyNow assay.32
Differently from our study, they have not found signiﬁcant
association between the preoperative AA-stimulated platelet
aggregation level and CV events,31 but they reported
a signiﬁcant association between postoperative AA-
stimulated platelet aggregation and troponin elevation.31
Although the deﬁnition of cardiac events in ours andRajaga-
palan’s study were different, as they have analyzed exclu-
sively postoperative troponin elevation, the incidence was
quite similar: 21%31 and 22% in the present study. It is
Table III. Results of the multivariate analysis of cardiovascular (CV) events risk predictors
Variable Category OR ORadjusted 95% CI ORadjusted P
Hemodynamic instability No
Yes
1.00
3.14
1.00
4.12
Ref.
1.87-9.06
<.001
Dyslipidemia No
Yes
1.00
3.10
1.00
3.90
Ref.
1.32-11.51
.014
Preoperative anemia No
Yes
1.00
2.19
1.00
2.64
Ref.
1.19-5.85
.017
AA platelet aggregability #11 U
>11 U
1.00
2.36
1.00
2.48
Ref.
1.07-5.76
.034
AA platelet aggregability, Platelet aggregability in response to arachidonic acid; CI, conﬁdence interval; OR, odds ratio; OR adjusted, odds ratio adjusted for
the predicted risk according to the American College of Physicians algorithm; Ref, reference.
Table IV. Platelet aggregation in patients with and without hemorrhagic events
Test Total Hemorrhagic event þ Hemorrhagic event  P
Impedance aggregometry
Collagen 1 mL/mL (U) 5.48 6 4.28 4.97 6 3.78 6.11 6 4.80 .079
Collagen 2 mL/mL (U) 10.48 6 5.27 10.17 6 5.43 10.88 6 5.10 .358
Collagen 5 mL/mL (U) 16.96 6 5.69 17.02 6 5.91 16.92 6 5.47 .914
AA 0.5 mM/mL (U) 5.83 6 5.90 5.98 6 5.89 5.60 6 5.96 .660
AA, Arachidonic acid.
Data are presented as mean 6 standard deviation.
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explains the different results. Another possibility relies on
the method applied for platelet aggregation measurement;
the VerifyNow is considered the best point of care method
but the comparison of results from different tests may be
a limitation.24
Regarding the other predictors of CV events, it was not
surprising that preoperative anemia increased the risk of
CV events after vascular surgery, as anemia is a recognized
risk marker for noncardiac surgery,33 and it is less well
tolerated in the presence of CV disease.34 The ﬁnding of
dyslipidemia as a perioperative risk marker was intriguing,
as every patient had high atherosclerotic disease burden
and almost 100% received statin therapy because of its peri-
operative indication. There is a clear recommendation in
various perioperative care guidelines to administer statin
to vascular surgery patients, regardless of the cholesterol
levels.1,2,10 It is possible that patients who informed the
diagnosis of dyslipidemia were patients with known coro-
nary artery disease at higher cardiac risk. We have already
shown in a previous study that coronary artery disease
patients are much more aware of their disease, and the
importance of risk factor control, than vascular surgery
patients.35
The presence of hemodynamic instability during anes-
thesia indicates a four-fold risk increase. We believe that
more than a clinical sign of the CV event, patients who
experience hemodynamic instability due to bleeding, vaso-
plegia, hypovolemia, or anesthetic effect experience uncon-
trolled myocardial oxygen supply demand mismatch that
can cause sudden ischemia (type II myocardial infarction)
or trigger further plaque disruption (type I myocardialinfarction). Actually, for our 21 patients with a CV event,
we found a delay between hemodynamic instability and
the CV event; 76.2% of the events occurred in the ﬁrst
48 hours after surgery, but only 38% were concentrated
in the ﬁrst 24 hours.
We did expect that the degree of platelet aggregation
would be inversely correlated to hemorrhagic events, but
fortunately, even when we analyzed the lowest quartile of
platelet aggregation in response to AA, there was no increase
in the rate of bleeding, reinforcing the security of aspirin
maintenance throughout the perioperative period.
The high incidence of hemorrhagic events (50.97%)
was a disturbing ﬁnding, but we believe that the TIMI
criteria oversized the magnitude of the problem in this
very speciﬁc perioperative context. We decided to adopt
the TIMI criteria for an objective classiﬁcation of events
considering the lack of a speciﬁc perioperative criterion
for hemorrhagic events. In the perioperative setting, there
is always some degree of acute blood loss, different than
what is expected for acute coronary syndromes, the setting
where the TIMI criteria were validated.19 When we analyze
exclusively the need for red blood cell transfusion of the
patients submitted to aortic aneurysm repair, the 34.3%
rate found in our study is in accordance with the transfu-
sion rate reported in the literature. In the Dutch Random-
ized Endovascular Aneurysm Management (DREAM)
trial, 39.13% of the 345 patients submitted to aortic aneu-
rysm repair received blood transfusion (6% for the endovas-
cular group and 72% for the open repair group).36 In the
429 open aneurysm repair patients enrolled in the Open
Versus Endovascular Repair (OVER) trial, the authors
observed a median of 1.000 mL of blood loss during
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information of the TIMI criteria for the perioperative
context, in our study, we decided to maintain it for statis-
tical analysis because it is more complete and less subject to
bias than the transfusion requirement, as the transfusion
decision was at the discretion of the attending physicians,
without uniform criteria.
Although it is very tempting to consider that the
current results indicate that therapeutic adjustment of
platelet aggregation could possibly interfere with perioper-
ative CV morbidity and mortality, it is important to
remember that this study was not designed to test any
intervention.
There are some study limitations. We did not obtain the
thromboxane B2 serum levels that could provide additive
information about aspirin effect. But we believe that the
results from the impedance aggregometry test indicating
association of the platelet response exclusively to AA agonist
andCV events already indicate the prognostic importance of
individual aspirin response. The heterogeneity of the
vascular procedures in the study population could be consid-
ered another limitation, but considering that the primary
end point was CV events, that the mechanisms involved in
the pathogenesis of CV complications in the perioperative
setting of these different surgical interventions is
similar,1,2,13 and that previous studies have included the
same population as a whole group,8,9,22,30 we do not believe
that it could affect the conclusions of the study. Data
regarding platelet aggregation after AA stimuli allowed the
identiﬁcation of different reference ranges. Despite being
the result of post-hoc analysis, we found that this ﬁnding
is very important as it is more representative from the clinical
standpoint. Future studies including an increased number of
patients must strongly consider the reference ranges and
cut-offs proposed in the present study.
So, we conclude that the degree of aspirin effect is
important in the management of perioperative morbidity
and mortality, reinforcing the putative importance of ath-
erothrombosis in the physiopathology of CV complications
after vascular surgery.2 Aspirin dose titration is a potential
tool for perioperative risk management, but conﬁrmation
of the optimal platelet aggregation level and targeted
aspirin dose titration studies are still needed.
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